Premium
P4–171: Risk score for the prediction of Alzheimer's disease progression in people with amnestic mild cognitive impairment: A multicenter, clinic‐based longitudinal study
Author(s) -
Ye Byoung Seok,
Chin Ju Hee,
Kim Seong Yoon,
Lee Jung Sun,
Kim EunJoo,
Lee Yunhwan,
Back Joung Hwan,
Hong Chang Hyung,
Choi Seong,
Park Kyung Won,
Ku Bon,
Moon So,
Kim Sang Yun,
Han SeolHeui,
Lee JaeHong,
Cheong HaeKwan,
Yang Dong Won,
Na Duk L.,
Seo Sang Won
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1562
Subject(s) - dementia , audiology , psychology , logistic regression , cognition , memory impairment , cognitive impairment , memory clinic , disease , medicine , psychiatry
memory impairment group (Both-aMCI), according to the performance in the memory tests applied to diagnose aMCI. A previous study suggested there were the hierarchical order in the cortical thinning among three aMCI groups. However, to our knowledge, the rates of Alzheimer’s disease (AD) progression between three aMCI groups have not been compared. Methods: From a multicenter hospital-based registry (CREDOS), we enrolled 562 aMCI patients and performed a prospective cohort study with mean follow-up duration of 19.7 months. There were 136 patients with Visual-aMCI, 135 with Verbal-aMCI, and 291 with Both-aMCI. The risks of AD progression between three aMCI groups were compared with Cox proportional hazard analyses using age, gender, and education as covariates. Gender-specific mixed effect models were used to compare longitudinal changes in neuropsychological scores according to aMCI subgroups. Results: During mean follow-up duration of 19.7 months, 176 (31.3%) patients progressed to AD and 48 (8.5%) reverted to normal cognition. VerbalaMCI group (adjusted HR: 1.80, 95% CI: 1.04-3.12) and Both-aMCI group (2.44, 1.55-3.84) had significantly higher risks of AD progression compared with Visual-aMCI group. In female patients, Visual-aMCI group exhibited slower decline in visuospatial function test, MMSE, and Clinical Deterioration Rating Sum of Boxes (CDR-SOB) than Both-aMCI group. In male patients, Verbal-aMCI group exhibited slower deterioration in language, attention, visual memory recognition tests, and CDR-SOB than BothaMCI group. Conclusions: Our findings suggest that Visual-aMCI group might be an earlier stage of developing AD or composed of pathologically heterogeneous entities other than AD. Gender-specific cognitive reserve might explain the slower cognitive decline in female Visual-aMCI and male Verbal-aMCI group.